A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome

Fertility and Sterility

Volumn 91, Issue 3, 2009, Pages 842-850

  Glintborg, Dorte ^a   Hermann, Anne Pernille ^a   Hagen, Claus ^a   Jensen, Lars Thorbjørn ^b   Frystyk, Jan ^c   Bennett, Paul ^d   Flyvbjerg, Allan ^c   Andersen, Marianne ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c Clinical Institute   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

adiponectin; cortisol; free fatty acids; growth hormone; IGF I; insulin sensitivity; PCOS; PPAR ; steroid metabolites

Indexed keywords

ADIPONECTIN; ANDROSTANOLONE; ANDROSTERONE; ETIOCHOLANOLONE; HYDROCORTISONE; INSULIN; PIOGLITAZONE; PLACEBO; PRASTERONE; PRASTERONE SULFATE; PYRIDOSTIGMINE; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TETRAHYDROCORTISOL;

ANKLE EDEMA; ANXIETY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID METABOLISM; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLITE; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; URINARY EXCRETION;

ADIPONECTIN; ANDROSTERONE; BLOOD GLUCOSE; DENMARK; ETIOCHOLANOLONE; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE; TETRAHYDROCORTISOL; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 61349122771     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.12.082     Document Type: Article

References (54)

1. Glintborg D., Hermann A.P., Brusgaard K., Hangaard J., Hagen C., and Andersen M. Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clin Endocrinol Metab 90 (2005) 1347-1353
2. Azziz R., Black V., Hines G.A., Fox L.M., and Boots L.R. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 83 (1998) 2317-2323
3. Kelestimur F., and Sahin Y. Alternate pathway 17,20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome. Fertil Steril 71 (1999) 1075-1078
4. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 13 (1997) 795-803
5. Stewart P.M., Shackleton C.H., Beastall G.H., and Edwards C.R. 5 Alpha-reductase activity in polycystic ovary syndrome. Lancet 335 (1990) 431-433
6. Rodin A., Thakkar H., Taylor N., and Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med 330 (1994) 460-465
7. Chin D., Shackleton C., Prasad V.K., Kohn B., David R., Imperato-McGinley J., et al. Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome. J Pediatr Endocrinol Metab 13 (2000) 253-259
8. Fassnacht M., Schlenz N., Schneider S.B., Wudy S.A., Allolio B., and Arlt W. Beyond adrenal and ovarian androgen generation: increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2760-2766
9. Draper N., and Stewart P.M. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 186 (2005) 251-271
10. Tomlinson J.W., and Stewart P.M. Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 15 (2001) 61-78
11. Archer J.S., and Chang R.J. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18 (2004) 737-754
12. Skalba P., Dabkowska-Huc A., Kazimierczak W., Samojedny A., Samojedny M.P., and Chelmicki Z. Content of 5-alpha-reductase (type 1 and type 2) mRNA in dermal papillae from the lower abdominal region in women with hirsutism. Clin Exp Dermatol 31 (2006) 564-570
13. Serafini P., and Lobo R.A. Increased 5 alpha-reductase activity in idiopathic hirsutism. Fertil Steril 43 (1985) 74-78
14. Tsilchorozidou T., Honour J.W., and Conway G.S. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab 88 (2003) 5907-5913
15. Jakimiuk A.J., Weitsman S.R., and Magoffin D.A. 5alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 84 (1999) 2414-2418
16. Glintborg D., Henriksen J.E., Andersen M., Hagen C., Hangaard J., Rasmussen P., et al. The prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 caucasian, premenopausal women with hirsutism as primary diagnosis. Fertil Steril 82 (2004) 1570-1579
17. Franks S. Growth hormone and ovarian function. Baillieres Clin Endocrinol Metab 12 (1998) 331-340
18. Homburg R. Growth hormone and fertility-clinical studies. Horm Res 45 (1996) 81-85
19. Lord J.M., Flight I.H., and Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev (2003) CD003053
20. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (2003) 951-953
21. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002) 797-802
22. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87 (2002) 2784-2791
23. Glintborg D., Stoving R.K., Hagen C., Hermann A.P., Frystyk J., Veldhuis J.D., et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 5605-5612
24. Livingstone D.E., Kenyon C.J., and Walker B.R. Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 167 (2000) 533-539
25. Glintborg D., Hermann A.P., Andersen M., Hagen C., Beck-Nielsen H., Veldhuis J.D., and Henriksen J.E. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 86 (2006) 385-397
26. Lykkesfeldt G., Bennett P., Lykkesfeldt A.E., Micic S., Moller S., and Svenstrup B. Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clin Endocrinol (Oxf) 23 (1985) 385-393
27. Frystyk J., Dinesen B., and Orskov H. Noncompetitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 5 (1995) 169-176
28. Frystyk J., Tarnow L., Krarup H.T., Parving H.H., and Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48 (2005) 1911-1918
29. Nielsen M.D., Lund J.O., and Munck O. Urinary excretion of tetrahydroaldosterone in normal subjects and in patients with adrenal insufficiency and Conn's syndrome. Acta Endocrinol (Copenh) 71 (1972) 498-511
30. Nielsen M.D., Binder C., and Starup J. Urinary excretion of different corticosteroid-metabolites in oral contraception and pregnancy. Acta Endocrinol (Copenh) 60 (1969) 473-485
31. Palermo M., Shackleton C.H., Mantero F., and Stewart P.M. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 45 (1996) 605-611
32. Shackleton C.H. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol 45 (1993) 127-140
33. Pincus S.M. Approximate entropy as a measure of system complexity. Proc Natl Acad Sci U S A 88 (1991) 2297-2301
34. Altman D.G. Practical statistics for medical research (1991), Chapman & Hall/CRC, London, UK 199-202
35. Dunaif A., Xia J., Book C.B., Schenker E., and Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96 (1995) 801-810
36. Zhang L.H., Rodriguez H., Ohno S., and Miller W.L. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 92 (1995) 10619-10623
37. Romualdi D., Giuliani M., Draisci G., Costantini B., Cristello F., Lanzone A., and Guido M. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 88 (2007) 131-138
38. Romualdi D., Guido M., Ciampelli M., Giuliani M., Leoni F., Perri C., and Lanzone A. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 18 (2003) 1210-1218
39. Brettenthaler N., De Geyter C., Huber P.R., and Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 3835-3840
40. Guido M., Romualdi D., Suriano R., Giuliani M., Costantini B., Apa R., and Lanzone A. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 19 (2004) 534-539
41. Charbonneau A., and The V.L. Genomic organization of a human 5beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme. Biochim Biophys Acta 1517 (2001) 228-235
42. Walker B.R., Rodin A., Taylor N.F., and Clayton R.N. Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome. Clin Endocrinol (Oxf) 52 (2000) 77-80
43. Berger J., Tanen M., Elbrecht A., Hermanowski-Vosatka A., Moller D.E., Wright S.D., and Thieringer R. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 276 (2001) 12629-12635
44. Glintborg D., Hermann A., Brusgaard K., Hangaard J., Hagen C., and Andersen M. Significantly higher ACTH-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared to healthy controls. J Clin Endocrinol Metab 90 (2005) 1347-1353
45. Vrbikova J., Bicikova M., Tallova J., Hill M., and Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 110 (2002) 74-76
46. Kazerooni T., and Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 17 (2003) 51-56
47. Unluhizarci K., Kelestimur F., and Bayram F. Insulin-sensitizing agents and their effect on adrenal androgens. Fertil Steril 74 (2000) 1058-1059
48. Mitkov M., Pehlivanov B., and Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 126 (2006) 93-98
49. Arslanian S.A., Lewy V., Danadian K., and Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 87 (2002) 1555-1559
50. La Marca A., Morgante G., Paglia T., Ciotta L., Cianci A., and De Leo V. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 72 (1999) 985-989
51. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fereshetian A.G., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
52. Glueck C.J., Moreira A., Goldenberg N., Sieve L., and Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 18 (2003) 1618-1625
53. Dunaif A., Scott D., Finegood D., Quintana B., and Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81 (1996) 3299-3306
54. Rautio K., Tapanainen J.S., Ruokonen A., and Morin-Papunen L.C. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 21 (2006) 1400-1407